Could a dab of liquid under the tongue replace weekly weight-loss shots?

NCT ID NCT07728383

Recruiting now Disease control Sponsor: Gila Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether a liquid form of semaglutide, applied under the tongue, can help adults with obesity lose weight. Semaglutide is a hormone-like drug that reduces appetite. The study compares the liquid to a standard semaglutide tablet and a placebo. Researchers want to see if this new delivery method is safe, tolerable, and effective for weight loss over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a topical-lingual liquid emulsion formulation of semaglutide, a GLP-1 receptor agonist that helps control appetite
What this could lead to: If successful, this could offer a new, more convenient way to deliver semaglutide for weight management without injections.
What could go wrong: This is a small, early proof-of-concept trial with only 40 participants. The new delivery method may not work as well as the injectable form, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Clinical Research Institute of Minnesota
RECRUITING

Minneapolis, Minnesota, 55402, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.